Growth Support Patch "Hautuki" Evaluated for Safety and Efficacy Through Clinical and Usage Studies

CUSTICS SINGAPORE PTE. LTD. stated that it conducted long-term usage and controlled clinical studies on its growth support patch "Hautuki" with an external medical institution. The studies involved children aged 5 to 12 and included safety observation and a placebo-controlled trial, in which the Hautuki group showed a higher average height increase than the control group. The company is also expanding its business through its Japanese D2C platform and Qoo10 Japan.
CUSTICS SINGAPORE PTE. LTD., a Singapore-based consumer innovation company, announced on the 8th that it has conducted a series of studies on its growth support patch "Hautuki" with the aim of providing greater reassurance to customers and demonstrating evaluation practices aligned with internationally recognized standards.

According to the company, a long-term usage evaluation study was carried out in collaboration with an external medical institution between January and November 2024. The study involved 40 children aged 5 to 12, who were observed over a period of approximately 11 months to assess safety-related outcomes associated with continued product use.

In addition, the company explained that a controlled clinical study was conducted involving 40 children aged between 5 and 12. Participants were divided into a test group, which applied the Hautuki patch, and a control group, which applied a placebo patch. The trial was conducted over an eight-week period. Under the conditions of the study, the group using the Hautuki patch recorded an average height increase of approximately 0.4 cm more than the control group, corresponding to a relative increase of about 30%.

The company stated that these studies were designed to evaluate the product through structured methodologies, including the use of control and placebo groups, in order to provide customers with a higher level of confidence in both product safety and evaluation rigor.

Kang-Il Lee, Chief Executive Officer of CUSTICS SINGAPORE PTE. LTD., commented, "Our objective has been to evaluate the product through objective and structured research processes so that customers can make informed decisions with confidence. We believe that maintaining evaluation standards consistent with global practices is essential for building long-term trust."

Beyond its research initiatives, CUSTICS SINGAPORE PTE. LTD. has recently expanded its business through its proprietary Japanese direct-to-consumer platform as well as Qoo10 Japan. Building on its presence in Asia, the company continues to broaden its reach into global markets.

In the growth support product market, the availability of structured safety data and controlled evaluation results is increasingly regarded as an important factor in customer confidence. While further research is generally required to establish broader conclusions, the company's approach reflects an effort to integrate research-based evaluation with international business expansion.

Media Contact
Company Name: Glovertise
Contact Person: Erick
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=growth-support-patch-hautuki-evaluated-for-safety-and-efficacy-through-clinical-and-usage-studies]
Phone: 01091916367
City: Singapore
Country: Singapore
Website: http://glovertise.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.